Tezepelumab reduced inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with or without asthma: results from the Phase 3 WAYPOINT study Meeting Abstract

publication date

  • March 1, 2026

webpage

published in

volume

  • 80